Top

Journal of Autism and Developmental Disorders

Gepubliceerd in:

29-08-2019 | Original Paper

Pharmacologic Interventions for Irritability, Aggression, Agitation and Self-Injurious Behavior in Fragile X Syndrome: An Initial Cross-Sectional Analysis

Auteurs: Eleanor M. Eckert, Kelli C. Dominick, Ernest V. Pedapati, Logan K. Wink, Rebecca C. Shaffer, Howard Andrews, Tse-Hwei Choo, Chen Chen, Walter E. Kaufmann, Nicole Tartaglia, Elizabeth M. Berry-Kravis, Craig A. Erickson

Gepubliceerd in: Journal of Autism and Developmental Disorders | Uitgave 11/2019

Abstract

Using a dataset involving 415 individuals with irritability, aggression, agitation and self-injury (IAAS) behaviors from the fragile X syndrome (FXS) FORWARD database, we describe the psychopharmacologic management of IAAS and features of the population of persons with FXS treated with drug therapy for IAAS. Among those with FXS exhibiting IAAS, individuals with FXS receiving drug treatment of IAAS were older, more predominantly male, have more significant intellectual disability, more like to have comorbid autism, hyperarousal, and social impairments. The most commonly utilized medications for IAAS in FXS are antipsychotic medications, specifically aripiprazole and risperidone (37% and 27%, respectively). The majority of subjects (63%) experienced no side effects noted from the use of their psychopharmacologic medications.

vorige artikel Social Validity and Teachers’ Use of Evidence-Based Practices for Autism

volgende artikel Characteristics, Early Development and Outcome of Parent-Reported Regression in Autism Spectrum Disorder

Aman, M. G., Singh, N. N., Stewart, A. W., & Field, C. J. (1985). The aberrant behavior checklist: A behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency, 5, 485–491.

Bailey, D. B., Jr., Hatton, D. D., Skinner, M., & Mesibov, G. (2001a). Autistic behavior, FMR1 protein, and developmental trajectories in young males with fragile X syndrome. Journal of Autism and Developmental Disorders, 31(2), 165–174.CrossRef

Bailey, D. B., Jr., Hatton, D. D., Tassone, F., Skinner, M., & Taylor, A. K. (2001b). Variability in FMRP and early development in males with fragile X syndrome. American Journal of Mental Retardation, 106(1), 16–27. https://doi.org/10.1352/0895-8017(2001)106%3c0016:VIFAED%3e2.0.CO;2.CrossRefPubMed

Bailey, D. B., Jr., Mesibov, G. B., Hatton, D. D., Clark, R. D., Roberts, J. E., & Mayhew, L. (1998). Autistic behavior in young boys with fragile X syndrome. Journal of Autism and Developmental Disorders, 28(6), 499–508.CrossRef

Bailey, D. B., Jr., Raspa, M., Bishop, E., Mitra, D., Martin, S., Wheeler, A., et al. (2012a). Health and economic consequences of fragile X syndrome for caregivers. Journal of Developmental and Behavioral Pediatrics, 33(9), 705–712. https://doi.org/10.1097/DBP.0b013e318272dcbc.CrossRefPubMed

Bailey, D. B., Jr., Raspa, M., Bishop, E., Olmsted, M., Mallya, U. G., & Berry-Kravis, E. (2012b). Medication utilization for targeted symptoms in children and adults with fragile X syndrome: US survey. Journal of Developmental and Behavioral Pediatrics, 33(1), 62–69. https://doi.org/10.1097/DBP.0b013e318236c0e1.CrossRefPubMed

Bailey, D. B., Jr., Raspa, M., Olmsted, M., & Holiday, D. B. (2008). Co-occurring conditions associated with FMR1 gene variations: Findings from a national parent survey. American Journal of Medical Genetics Part A, 146A(16), 2060–2069. https://doi.org/10.1002/ajmg.a.32439.CrossRefPubMed

Berry-Kravis, E., & Potanos, K. (2004). Psychopharmacology in fragile X syndrome—Present and future. Mental Retardation and Developmental Disabilities Research Reviews, 10(1), 42–48. https://doi.org/10.1002/mrdd.20007.CrossRefPubMed

Berry-Kravis, E., Sumis, A., Hervey, C., & Mathur, S. (2012). Clinic-based retrospective analysis of psychopharmacology for behavior in fragile X syndrome. International Journal of Pediatrics, 2012, 843016. https://doi.org/10.1155/2012/843016.CrossRefPubMedPubMedCentral

Budimirovic, D. B., & Kaufmann, W. E. (2011). What can we learn about autism from studying fragile X syndrome? Developmental Neuroscience, 33(5), 379–394. https://doi.org/10.1159/000330213.CrossRefPubMedPubMedCentral

Chevreul, K., Berg Brigham, K., Brunn, M., des Portes, V., & Network, B.-R. R. (2015). Fragile X syndrome: Economic burden and health-related quality of life of patients and caregivers in France. Journal of Intellectual Disability Research, 59(12), 1108–1120. https://doi.org/10.1111/jir.12215.CrossRefPubMed

Chevreul, K., Gandre, C., Brigham, K. B., Lopez-Bastida, J., Linertova, R., Oliva-Moreno, J., et al. (2016). Social/economic costs and health-related quality of life in patients with fragile X syndrome in Europe. The European Journal of Health Economics, 17(Suppl 1), 43–52. https://doi.org/10.1007/s10198-016-0784-3.CrossRefPubMed

Constantino, J. N., Davis, S. A., Todd, R. D., Schindler, M. K., Gross, M. M., Brophy, S. L., et al. (2003). Validation of a brief quantitative measure of autistic traits: Comparison of the social responsiveness scale with the autism diagnostic interview-revised. Journal of Autism and Developmental Disorders, 33(4), 427–433.CrossRef

Cordeiro, L., Ballinger, E., Hagerman, R., & Hessl, D. (2011a). Clinical assessment of DSM-IV anxiety disorders in fragile X syndrome: Prevalence and characterization. Journal of Neurodevelopmental Disorders, 3(1), 57–67. https://doi.org/10.1007/s11689-010-9067-y.CrossRefPubMed

Cordeiro, L., Ballinger, E., Hagerman, R., & Hessl, D. (2011b). Clinical assessment of DSM-IV anxiety disorders in fragile X syndrome: Prevalence and characterization. Journal of Neurodevelopmental Disorders, 3(1), 57–67. https://doi.org/10.1007/s11689-010-9067-y.CrossRefPubMed

Erickson, C. A., Davenport, M. H., Schaefer, T. L., Wink, L. K., Pedapati, E. V., Sweeney, J. A., et al. (2017). Fragile X targeted pharmacotherapy: Lessons learned and future directions. Journal of Neurodevelopmental Disorders, 9, 7. https://doi.org/10.1186/s11689-017-9186-9.CrossRefPubMedPubMedCentral

Erickson, C. A., Stigler, K. A., Posey, D. J., & McDougle, C. J. (2005). Risperidone in pervasive developmental disorders. Expert Review of Neurotherapeutics, 5(6), 713–719. https://doi.org/10.1586/14737175.5.6.713.CrossRefPubMed

Erickson, C. A., Stigler, K. A., Posey, D. J., & McDougle, C. J. (2010). Aripiprazole in autism spectrum disorders and fragile X syndrome. Neurotherapeutics, 7(3), 258–263. https://doi.org/10.1016/j.nurt.2010.04.001.CrossRefPubMedPubMedCentral

Erickson, C. A., Stigler, K. A., Wink, L. K., Mullett, J. E., Kohn, A., Posey, D. J., et al. (2011). A prospective open-label study of aripiprazole in fragile X syndrome. Psychopharmacology (Berl), 216(1), 85–90. https://doi.org/10.1007/s00213-011-2194-7.CrossRef

Guy, W. (1976). ECDEU assessment manual for psychopharmacology. Publication no. 76-338. Washington, DC: U.S. DHEW, NIMH.

Haessler, F., Gaese, F., Huss, M., Kretschmar, C., Brinkman, M., Peters, H., et al. (2016). Characterization, treatment patterns, and patient-related outcomes of patients with Fragile X syndrome in Germany: Final results of the observational EXPLAIN-FXS study. BMC Psychiatry, 16(1), 318. https://doi.org/10.1186/s12888-016-1020-5.CrossRefPubMedPubMedCentral

Hagerman, R. J., & Hagerman, P. J. (2008). Testing for fragile X gene mutations throughout the life span. JAMA, 300(20), 2419–2421. https://doi.org/10.1001/jama.2008.684.CrossRefPubMedPubMedCentral

Hagerman, R. J., & Polussa, J. (2015). Treatment of the psychiatric problems associated with fragile X syndrome. Current Opinion in Psychiatry, 28(2), 107–112. https://doi.org/10.1097/YCO.0000000000000131.CrossRefPubMedPubMedCentral

Hatton, D. D., Bailey, D. B., Jr., Hargett-Beck, M. Q., Skinner, M., & Clark, R. D. (1999). Behavioral style of young boys with fragile X syndrome. Developmental Medicine and Child Neurology, 41(9), 625–632.CrossRef

Hatton, D. D., Wheeler, A. C., Skinner, M. L., Bailey, D. B., Sullivan, K. M., Roberts, J. E., et al. (2003). Adaptive behavior in children with fragile X syndrome. American Journal of Mental Retardation, 108(6), 373–390. https://doi.org/10.1352/0895-8017(2003)108%3c373:ABICWF%3e2.0.CO;2.CrossRefPubMed

Hernandez, R. N., Feinberg, R. L., Vaurio, R., Passanante, N. M., Thompson, R. E., & Kaufmann, W. E. (2009). Autism spectrum disorder in fragile X syndrome: A longitudinal evaluation. American Journal of Medical Genetics Part A, 149A(6), 1125–1137. https://doi.org/10.1002/ajmg.a.32848.CrossRefPubMedPubMedCentral

Kaufmann, W. E., Abrams, M. T., Chen, W., & Reiss, A. L. (1999). Genotype, molecular phenotype, and cognitive phenotype: Correlations in fragile X syndrome. American Journal of Medical Genetics, 83(4), 286–295.CrossRef

Kaufmann, W. E., Kidd, S. A., Andrews, H. F., Budimirovic, D. B., Esler, A., Haas-Givler, B., et al. (2017). Autism spectrum disorder in fragile X syndrome: Cooccurring conditions and current treatment. Pediatrics, 139(Suppl 3), S194–S206. https://doi.org/10.1542/peds.2016-1159F.CrossRefPubMedPubMedCentral

Lewis, P., Abbeduto, L., Murphy, M., Richmond, E., Giles, N., Bruno, L., et al. (2006). Cognitive, language and social-cognitive skills of individuals with fragile X syndrome with and without autism. Journal of Intellectual Disability Research, 50(Pt 7), 532–545. https://doi.org/10.1111/j.1365-2788.2006.00803.x.CrossRefPubMed

Loesch, D. Z., Huggins, R. M., & Hagerman, R. J. (2004). Phenotypic variation and FMRP levels in fragile X. Mental Retardation and Developmental Disabilities, 10(1), 31–41. https://doi.org/10.1002/mrdd.20006.CrossRef

McClellan, L., Pedapati, E., Wink, L., & Erickson, C. (2016). Evidence-based pharmacotherapy for autism spectrum disorders. Current Treatment Options in Psychiatry, 3(2), 161–181. https://doi.org/10.1007/s40501-016-0077-6.CrossRef

McDougle, C. J., Stigler, K. A., Erickson, C. A., & Posey, D. J. (2008). Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders. Journal of Clinical Psychiatry, 69(Suppl 4), 15–20.PubMed

Posey, D. J., Stigler, K. A., Erickson, C. A., & McDougle, C. J. (2008). Antipsychotics in the treatment of autism. Journal of Clinical Investigation, 118(1), 6–14. https://doi.org/10.1172/JCI32483.CrossRefPubMed

Sansone, S. M., Widaman, K. F., Hall, S. S., Reiss, A. L., Lightbody, A., Kaufmann, W. E., et al. (2012). Psychometric study of the aberrant behavior checklist in fragile X syndrome and implications for targeted treatment. Journal of Autism and Developmental Disorders, 42(7), 1377–1392. https://doi.org/10.1007/s10803-011-1370-2.CrossRefPubMedPubMedCentral

Sherman, S. L., Kidd, S. A., Riley, C., Berry-Kravis, E., Andrews, H. F., Miller, R. M., et al. (2017). FORWARD: A registry and longitudinal clinical database to study fragile X syndrome. Pediatrics, 139(Suppl 3), S183–S193. https://doi.org/10.1542/peds.2016-1159E.CrossRefPubMedPubMedCentral

Symons, F. J., Byiers, B. J., Raspa, M., Bishop, E., & Bailey, D. B. (2010). Self-injurious behavior and fragile X syndrome: Findings from the national fragile X survey. American Journal on Intellectual and Developmental Disabilities, 115(6), 473–481. https://doi.org/10.1352/1944-7558-115.6.473.CrossRefPubMed

Symons, F. J., Clark, R. D., Hatton, D. D., Skinner, M., & Bailey, D. B., Jr. (2003). Self-injurious behavior in young boys with fragile X syndrome. American Journal of Medical Genetics Part A, 118A(2), 115–121. https://doi.org/10.1002/ajmg.a.10078.CrossRefPubMed

Tsiouris, J. A., & Brown, W. T. (2004). Neuropsychiatric symptoms of fragile X syndrome: Pathophysiology and pharmacotherapy. CNS Drugs, 18(11), 687–703.CrossRef

Wheeler, A. C., Raspa, M., Bishop, E., & Bailey, D. B., Jr. (2016). Aggression in fragile X syndrome. Journal of Intellectual Disability Research, 60(2), 113–125. https://doi.org/10.1111/jir.12238.CrossRefPubMed

Williams, K., Brignell, A., Randall, M., Silove, N., & Hazell, P. (2013). Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database Systematic Review, 8, CD004677. https://doi.org/10.1002/14651858.cd004677.pub3.CrossRef

Witwer, A. N., & Lecavalier, L. (2007). Autism screening tools: An evaluation of the Social Communication Questionnaire and the Developmental Behaviour Checklist-Autism Screening Algorithm. Journal of Intellectual Developmental Disability, 32(3), 179–187. https://doi.org/10.1080/13668250701604776.CrossRefPubMed

Titel: Pharmacologic Interventions for Irritability, Aggression, Agitation and Self-Injurious Behavior in Fragile X Syndrome: An Initial Cross-Sectional Analysis
Auteurs: Eleanor M. Eckert
Kelli C. Dominick
Ernest V. Pedapati
Logan K. Wink
Rebecca C. Shaffer
Howard Andrews
Tse-Hwei Choo
Chen Chen
Walter E. Kaufmann
Nicole Tartaglia
Elizabeth M. Berry-Kravis
Craig A. Erickson
Publicatiedatum: 29-08-2019
Uitgeverij: Springer US
Gepubliceerd in: Journal of Autism and Developmental Disorders / Uitgave 11/2019
Print ISSN: 0162-3257
Elektronisch ISSN: 1573-3432
DOI: https://doi.org/10.1007/s10803-019-04173-z

Andere artikelen Uitgave 11/2019

Spanish Validation of the Autism Quotient Short Form Questionnaire for Adults with Autism Spectrum Disorder

Original Paper

Clinical Profile of Autism Spectrum Disorder in a Pediatric Population from Northern Mexico

Original Paper

Effects of Diagnostic Severity upon Sex Differences in Behavioural Profiles of Young Males and Females with Autism Spectrum Disorder

Original Paper

The Interplay of Communication Skills, Emotional and Behavioural Problems and Parental Psychological Distress

Original Paper

Seeking Team Collaboration, Dialogue and Support: The Perceptions of Multidisciplinary Staff-Members Working in ASD Preschools

Original Paper

Expression Recognition Difficulty Is Associated with Social But Not Attention-to-Detail Autistic Traits and Reflects Both Alexithymia and Perceptual Difficulty

Original Paper